Publicaciones científicas

Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies

06-feb-2024 | Revista: Cardiovascular Interventional Radiology

Peter Reimer  1 , Valérie Vilgrain  2   3 , Dirk Arnold  4 , Tugsan Balli  5 , Rita Golfieri  6 , Romaric Loffroy  7 , Cristina Mosconi  6 , Maxime Ronot  2   3 , Christian Sengel  8 , Niklaus Schaefer  9 , Geert Maleux  10 , Graham Munneke  11 , Bora Peynircioglu  12 , Bruno Sangro  13 , Nathalie Kaufmann  14 , Maria Urdaniz  14 , Helena Pereira  15   16 , Niels de Jong  17 , Thomas Helmberger  18

Purpose: Transarterial radioembolization (TARE) with Yttrium-90 resin microspheres is a treatment option for patients with intrahepatic cholangiocarcinoma (ICC). However, optimising the timing of TARE in relation to systemic therapies and patient selection remains challenging. We report here on the effectiveness, safety, and prognostic factors associated with TARE for ICC in a combined analysis of the prospective observational CIRT studies (NCT02305459 and NCT03256994).

Methods: A combined analysis of 174 unresectable ICC patients enrolled between 2015 and 2020 was performed. Patient characteristics and treatment-related data were collected at baseline; adverse events and time-to-event data (overall survival [OS], progression-free survival [PFS] and hepatic PFS) were collected at every follow-up visit. Log-rank tests and a multivariable Cox proportional hazard model were used to identify prognostic factors.

Results: Patients receiving a first-line strategy of TARE in addition to any systemic treatment had a median OS and PFS of 32.5 months and 11.3 months. Patients selected for first-line TARE alone showed a median OS and PFS of 16.2 months and 7.4 months, whereas TARE as 2nd or further treatment-line resulted in a median OS and PFS of 12 and 9.3 months (p = 0.0028), and 5.1 and 3.5 months (p = 0.0012), respectively. Partition model dosimetry was an independent predictor for better OS (HR 0.59 [95% CI 0.37-0.94], p = 0.0259). No extrahepatic disease, no ascites, and < 6.1 months from diagnosis to treatment were independent predictors for longer PFS.

Conclusion: This combined analysis indicates that in unresectable ICC, TARE in combination with any systemic treatment is a promising treatment option.

CITA DEL ARTÍCULO  Cardiovasc Intervent Radiol. 2024 Feb 6.
doi: 10.1007/s00270-023-03657-x

Nuestros autores